Notice/News
Notice/News
Number
Title
Date
1
[Notice] March 26, 2026 PTAB Decision: Summary and Outlook
2026.03.30
2
[edaily] “ToolGen’s Yoo Jong‑sang Says CRISPR‑Cas9 Patent Battle Heats Up in H2, With Rising Pressure for a Three‑Party Deal”
2026.03.26
3
[Notice] ToolGen to Form Science Advisory Board (SAB)
2026.03.25
4
[Notice] CRISPR RNP Patent Status update(US,EU)
2026.03.18
5
[Financial Economy Plus] CRISPR, Part 4: Opening Act of a ‘Licensing Boom’—ToolGen Steps Beyond a Royalty Hub to the Center of Global Collaboration
2026.03.02
6
[Financial Economy Plus] CRISPR, Part 3: Platform Advantage — “Time Is on ToolGen’s Side” as Protracted Disputes Prolong Monopoly Terms
2026.03.01
7
[Financial Economy Plus] CRISPR, Part 2: “Find Biotech’s ARM” — The Power of the ‘Standard Technology’ Dominating Gene Editing
2026.02.28
8
[Financial Economy Plus] CRISPR, Part 1: From Probability to Design as FDA Redraws the Gene‑Editing Profit Formula
2026.02.27
9
[Finance Economy Plus] “Patents are the sword; royalties are the shield” — ToolGen declares 2026 its inaugural year for monetizing gene‑editing “scissors.”
2026.02.18
10
[Press Release] ToolGen Enters 'Harvest Season' for Global IP Monetization ; Appoints Litigation & Negotiation Expert Dave Koo as CLO
2026.02.12
11
[Notice] CRISPR RNP Patent Status update(US,EU)
2026.02.04
12
[Biz watch] ToolGen Speeds Up in H1 Amid 10‑Year Patent Dispute
2026.01.27
13
[BIO Insight] ToolGen, Confident in Patent Battle Win: ‘We’ll Commercialize Gene‑Editing IP’
2026.01.25
14
[Notice] ToolGen Secures Decision to Resume CRISPR-Cas9 Interference Proceedings as Senior Party
2026.01.21
15
[Notice] Frequently Asked Questions (FAQ)
2026.01.15